Publicaciones científicas
Use and safety of remdesivir in kidney transplant recipients with COVID-19
Anna Buxeda 1 , Carlos Arias-Cabrales 1 , María José Pérez-Sáez 1 , Judit Cacho 2 , Sheila Cabello Pelegrin 3 , Edoardo Melilli 4 , María José Aladrén 5 , Cristina Galeano 6 , Inmaculada Lorenzo 7 , Auxiliadora Mazuecos 8 , Isabel María Saura 9 , Antonio Franco 10 , María Del Carmen Ruiz-Fuentes 11 , Luis Alberto Sánchez-Cámara 12 , Orlando Siverio 13 , María Luisa Martin 14 , Elena González-García 15 , Verónica López 16 , Paloma Leticia Martin-Moreno 17 , Iñigo Moina 18 , Esperanza Moral Berrio 19 , Francesc Moreso 20 , José María Portolés 21 , Raquel Santana-Estupiñán 22 , Sofía Zárraga 23 , Cristina Canal 24 , Emilio Sánchez-Álvarez 25 , Julio Pascual 1 , Marta Crespo 1
Introduction: Remdesivir has demonstrated antiviral activity against coronavirus, shortening the time to recovery in adults hospitalized with moderate/severe COVID-19.
Severe adverse events such as acute kidney injury (AKI) have been reported. There is little available data on the use and safety of remdesivir in kidney transplant (KT) recipients.
Methods: We present a multicenter cohort study of 51 KT recipients with COVID-19 treated with remdesivir. Outcomes and safety were assessed.
Results: Mean age at diagnosis was 60 years, with a median time since KT of 4.5 years. Mean time since admission to remdesivir was 2 days. Twenty-eight patients (54.9%) required mechanical ventilation (19 non-invasive). Mortality was 18.9%, markedly higher if ≥65 years-old (45% vs. 3.2% in younger patients). AKI was present in 27.7% of patients, but in 50% of cases it was diagnosed before treatment.
Remdesivir did not require discontinuation because of adverse events in any case. We did not find significant hepatoxicity or systemic symptoms resultant from the drug.
Conclusions: In our cohort of KT recipients, remdesivir was well tolerated and safe in terms of renal and hepatic toxicity, but randomized trials are needed to assess its efficacy.
CITA DEL ARTÍCULO Kidney Int Rep. 2021 Sep;6(9):2305-2315. doi: 10.1016/j.ekir.2021.06.023. Epub 2021 Jul 6
Nuestros autores
